We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Alliance to Develop HLA-Typing Method

By HospiMedica staff writers
Posted on 24 Oct 2001
A collaborative agreement to evaluate and develop methods for typing human leukocyte antigens (HLA) using a simple-to-use sequencing technology has been announced by Pel-Freez Clinical Systems LLC (Stockholm, Sweden) and the Molecular Diagnostics Business Unit of Pyrosequencing AB (Milwaukee, WI, USA). More...
The announcement was made at the conference of the American Society for Histocompatibility and Immunogenetics in San Francisco (CA, USA).

HLA genes are highly variable, which has a significant impact on patients undergoing organ and bone marrow transplantation. To achieve the highest clinical success, the goal in transplantation is to accurately match the patterns of HLA variability of the donor and patient. DNA-based method for HLA typing have enabled diagnostic labs to better identify appropriate donors. Pel-Freez and Pyrosequencing plan to base their new typing method on proprietary technology developed by Pyrosequencing. This technology is broadly applicable for the analysis of single nucleotide polymorphisms (SNPs) and for the identification and quantification of short DNA sequences used in bacterial and viral typing.

"We believe the Pyrosequencing platform will be truly novel in the HLA field with its ability to simultaneously deliver speed, resolving power, and versatility,” said Frank Langley, president of Pel-Freez.




Related Links:
Pyrosequencing
Pel-Freez

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.